Curis Stock Price, News & Analysis

Curis (CRIS) announced its Q3 2021 financial results, reporting a net loss of $11.1 million or $0.12 per share, compared to a loss of $6.0 million for Q3 2020. Revenues grew to $3.0 million from $2.7 million year-over-year. The company continues to advance its clinical trials for CA-4948 in AML, MDS, and B cell cancers, with a significant update expected in January 2022. Operating expenses increased to $13.1 million due to higher R&D costs. As of September 30, 2021, Curis had $149.8 million in cash, ensuring planned operations into 2024.

Curis, Inc. (NASDAQ: CRIS) announced new preclinical data for its investigational monoclonal antibody, CI-8993, at the Society for Immunotherapy of Cancer's 36th Annual Meeting. CI-8993 targets the immune checkpoint molecule VISTA, with a study conducted in collaboration with the Olivia Newton-John Cancer Research Institute confirming its binding properties. Future plans include a clinical trial involving patients with solid tumors. This research aligns with Curis's commitment to advancing cancer therapies and supports ongoing development in immuno-oncology.

Curis, Inc. (NASDAQ: CRIS) announced the first patient has been dosed in the Phase 1/2 clinical trial of CA-4948, an IRAK4 kinase inhibitor, aimed at patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS). This study will evaluate CA-4948 in combination with azacitidine and venetoclax, targeting improved treatment options for patients ineligible for intensive chemotherapy. Initial monotherapy results have been promising, and CA-4948 has received Orphan Drug Designation from the FDA.

Curis, Inc. (NASDAQ: CRIS) is set to release its third quarter 2021 financial results on November 9, 2021, after market close. Management will host a conference call at 4:30 PM ET to discuss the results. Curis focuses on innovative cancer therapeutics, holding exclusive licenses for several small molecule antagonists and conducting clinical trials for drugs like CA-4948 in non-Hodgkin's lymphoma and acute myeloid leukemia. Key collaborations include partnerships with Aurigene and Genentech for drug development and commercialization.

Curis, Inc. (NASDAQ: CRIS), a biotechnology firm focused on cancer therapeutics, has announced its participation in virtual events during November and December 2021. Key highlights include:

• Credit Suisse Healthcare Conference on November 8, featuring CEO Jim Dentzer.
• Jefferies Global Healthcare Conference on November 18, where Dentzer will also present.
• B. Riley Oncology Panel on December 1, featuring Robert Martell.

Live webcasts can be viewed on Curis's website, with archived replays available for 90 days.

Curis, Inc. (NASDAQ: CRIS) announced new preclinical data for its IRAK4 inhibitor, CA-4948, at the AACR-NCI-EORTC Virtual Conference. The data demonstrates CA-4948's potential in treating non-Hodgkin's lymphoma, acute myeloid leukemia, and myelodysplastic syndromes. Notably, the research indicates CA-4948 may synergize with existing therapies and effectively cross the blood-brain barrier, enhancing survival rates in aggressive CNS lymphoma. This supports ongoing Phase 1 clinical trials aimed at examining its effectiveness in various hematologic cancers.

Curis, Inc. (NASDAQ: CRIS) announced on October 1, 2021, that its Compensation Committee approved inducement stock options for five new employees, totaling 106,350 shares. Each option has a 10-year term and an exercise price set at the closing stock price on the grant date. Vested options will occur over four years, beginning with 25% vesting after the first year of employment. These grants are part of Curis's strategy to attract talent as it continues to develop innovative cancer therapies, including various ongoing clinical trials for its product candidates.

Curis, a biotechnology company focused on cancer therapeutics, announced the participation of CEO James Dentzer in two upcoming virtual healthcare conferences. The Morgan Stanley Virtual Global Healthcare Conference is set for September 10, 2021, at 11:00 a.m. ET, followed by the Cantor Virtual Global Healthcare Conference on September 30, 2021, at 9:20 a.m. ET. Presentations will be available via live webcast and later as a replay on Curis' investor website. Curis is developing key cancer drugs, including CA-4948, which is in clinical trials for non-Hodgkin's lymphoma and acute myeloid leukemia.

Curis, Inc. (NASDAQ: CRIS) reported its Q2 2021 financial results, showing a net loss of $10.8 million ($0.12/share), compared to a loss of $6.7 million in Q2 2020. Revenues slightly decreased to $2.3 million, primarily from royalties. The company continues to advance its pipeline, notably the IRAK4 inhibitor CA-4948, demonstrating positive data in clinical trials for AML/MDS patients. Operating expenses rose to $12.9 million due to increased R&D costs. Curis holds $160.7 million in cash, sufficient to fund operations into 2024.